Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.

Clinical pharmacology and therapeutics - 1 Aug 2003

Kirchheiner Julia, Kudlicz Dirk, Meisel Christian, Bauer Steffen, Meineke Ingolf, Roots Ivar, Brockmöller Jürgen

Abstract excerpt

INTRODUCTION: In vitro data indicate that biotransformation of the synthetic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor fluvastatin is catalyzed by the cytochrome P450 (CYP) enzyme 2C9. The consequences of CYP2C9 genetic polymorphisms on fluvastatin pharmacokinetics and on its efficacy have not been investigated in humans thus far. METHODS: Twenty-four healthy heterozygous or homozygous carriers of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Cholesterol, HDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Cytochrome P-450 CYP2C9

Share to Fatty Acids, Monounsaturated

Share to Indoles

Share to Pyridines

Share to Stereoisomerism

Source

Identifiers

PMID: 12891229
DOI: 10.1016/S0009-9236(03)00121-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.PMID 12891229Read ↗

Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.Semantic proximity Read ↗

Enantiospecific Pharmacogenomics of FluvastatinSemantic proximity Read ↗

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.Semantic proximity Read ↗

Clinical consequences of cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects.Semantic proximity Read ↗

The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects.Semantic proximity Read ↗

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Semantic proximity Read ↗

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele.Semantic proximity Read ↗

No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.Semantic proximity Read ↗

Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.Semantic proximity Read ↗

Differential genotype dependent inhibition of CYP2C9 in humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.